WOMAN Trial – Use of Tranexamic Acid (TXA) in Postpartum Hemorrhage

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Thursday, April 25, 2019 - On-Demand Available

Master Program Number: 19EL-426 (see program format numbers below under Registration)

  • Educational Track: Technical/Clinical
  • Topic: Patient Blood Management
  • Intended Audience: Directors, Hospital Blood Banks, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, PBM Coordinators, Perfusionists, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
  • Teaching Level: Advanced, Intermediate
  • Director/Moderator: Kathleen E. Puca, MD, Senior Medical Director, Medical Sciences Institute, BloodCenter of Wisconsin, Part of Versiti, BloodCenter of Wisconsin, Milwaukee, Wisconsin
    Speaker: Kerry O’Brien, MD, Medical Director Blood Bank & Clinical Pathology Residency Program Director, Beth Israel Deaconess Medical Center, Assistant Professor Pathology, Harvard Medical School, Boston, MA
  • Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Explain obstetric hemorrhage and any associated risk factors.
    • Summarize the evidence for use of tranexamic acid in non-obstetric hemorrhage.
    • Describe the data on tranexamic acid in postpartum hemorrhage.
    • Discuss the results of the WOMAN Trial and its potential impact on future management for postpartum hemorrhage.

    Program Description

    Obstetric hemorrhage is one of the leading, and most treatable, causes of maternal morbidity and mortality worldwide. Obstetric hemorrhage accounts for more than 27% of maternal deaths worldwide, with the majority being a result of postpartum hemorrhage. Anti-fibrinolytic agents have been widely used to reduce blood loss in non-obstetric surgical cases as well as traumatic injuries and have been proposed as a treatment for post-partum hemorrhage. A multinational group of investigators recently performed a randomized, double-blinded placebo-controlled trial of over 20,000 women looking at the effects of administration of 1 gram of intravenous tranexamic acid (TXA) as a potential candidate to treat post-partum hemorrhage.


    Program #
    Single Viewer: On-Demand Register 19EL-426-4031
    Group Viewing: On-Demand Register 19EL-426-8031

    Continuing Education Credit

    AABB designates both the live and on-demand version of this eCast each to be eligible for 1.0 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

    Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

    Speaker Biography

    Dr. Kerry O’Brien is currently the Medical Director of the Blood Bank at Beth Israel Deaconess Medical Center in Boston, MA. After growing up in Massachusetts, Dr. O’Brien graduated from Boston University School of Medicine in 2002 and completed residency in Anatomic and Clinical Pathology at Madigan Army Medical Center in Tacoma, WA in 2007. She then served as an attending pathologist at that same hospital for 4 years. She completed her Transfusion Medicine fellowship at Puget Sound Blood Center in Seattle (which is now known as Bloodworks Northwest) in 2012 after leaving the military. Dr. O’Brien has been at Beth Israel Deaconess Medical Center since 2012, where in addition to her duties as a Blood Banker, she has been the Clinical Pathology Residency Director since February 2016.